To further investigate if there was a potential correlation between the length of the anti-EGFR drug-free intervals and the disappearance of anti-EGFR cancer-resistant clones, we performed a descriptive analysis by using different time points from the last administration of anti-EGFR drugs in the first-line therapy (Figure 3). The gene discussed is EGFR; the disease is cancer.